ACTEMRA (Roche Products Pty Ltd)
Product name
ACTEMRA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
36 working days (120 COR-A)
Active ingredients
tocilizumab
Registration type
EOI
Indication
ACTEMRA (solution for injection) is now also indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older (IV formulation only).